TRAW — Traws Pharma Cashflow Statement
0.000.00%
- $7.57m
- -$13.76m
- $0.23m
Annual cashflow statement for Traws Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -25.2 | -16.2 | -19 | -18.9 | -167 |
Depreciation | |||||
Non-Cash Items | 0.577 | 0.255 | 1.17 | 1.3 | 143 |
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.49 | -3.59 | 1.48 | -0.301 | -6.57 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -23.1 | -19.5 | -16.3 | -17.9 | -29.8 |
Capital Expenditures | -0.015 | 0 | — | -0.014 | — |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | — | — | -3.65 |
Acquisition of Business | |||||
Cash from Investing Activities | -0.015 | 0 | — | -0.014 | -3.65 |
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 19.4 | 55.6 | 0 | — | 34 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -3.7 | 36 | -16.3 | -17.9 | 0.517 |